Press releaseBusiness Wire
Enveric Biosciences
ENVB · NASDAQ
$1.44+$0.05 (+3.60%)TodayMarket closed ·
Prev close $1.39
Latest news
- Press releaseBusiness Wire
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
- Press releaseBusiness Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
- NewsVandana Singh
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
- News
Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings Align With Previously Reported BRET Data
- Press releaseBusiness Wire
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
- Press releaseBusiness Wire
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
- Press releaseBusiness Wire
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Press releaseBusiness Wire
Enveric Biosciences Announces Participation in 2026 BIO International Convention
- Press releaseBusiness Wire
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
- Press releaseBusiness Wire
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
- Press releaseBusiness Wire
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
- Press releaseBusiness Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
- Press releaseBusiness Wire
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
- NewsVandana Singh
Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies
- Press releaseBusiness Wire
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releasePRNewswire
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
- NewsVandana Singh
What's Going On With Enveric Biosciences Stock On Friday?
- Press releaseBusiness Wire
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum
- NewsEvette Mitkov
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
- NewsAvi Kapoor
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
- NewsNamrata Sen
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
- Press releaseBusiness Wire
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Press releaseBusiness Wire
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- News
'Trump To Sign Executive Order On Psychedelic Drug Used Abroad To Treat PTSD' - CBS News Exclusive
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
- Press releaseBusiness Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Moves Lower; Photronics Shares Surge After Q4 Results
- NewsAvi Kapoor
US Stocks Mixed Ahead Of Fed Decision; Dow Surges 100 Points
- NewsAvi Kapoor
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.